No translate

Cao Mạnh Hưng; Nguyễn Thị Duyên; Phạm Bá Nha; Trương Thanh Hương

doi:10.58354/jvc.94.95.2021.173

Home

CA LÂM SÀNG Issue: Số 94+95 , 2021 BỆNH TIM BẨM SINH

No translate

Published: August 20, 2026

10.58354/jvc.94.95.2021.173

Abstract

No translate

Keywords

No translate

References

1. Buyon JP, Clancy RM, Fridman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal/foetal dyad at risk. J Intern Med. 2009;265:653-62.

DOI: doi.org/10.1111/j.1365-2796.2009.02100.x

2. Buyon JP, Clancy RM, Friedman DM. Cardiac Manifestations of Neonatal Lupus Erythematosus: guidelines to management integrating integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009;5:139–48.

3. Buyon JP, Hiebert R, Copel J et al. Autoimmune-associated congenital heart block: Mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658–66.

DOI: doi.org/10.1038/ncprheum1018

4. Carolis SD, Salvi S, Botta A et al. Which Intrauterine Treatment for Autoimmune Congenital Heart Block? Open Autoimmunity Journal. 2010;2:1-10.

5. Costedoat-ChalumeauN,AmouraZ,LeThiHong D et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis. 2003;62:1010-2.

DOI: doi.org/10.1016/s0735-1097(98)00161-2

6. Friedman DM, Llanos C, Izmirly PM et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62:1138–46.

7. FriedmanDM,KimMY,CopelJAetal. Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block.

8. Ambrosi A, Dzikaite V, Park J, et al. AntiRo52 monoclonal antibodies specific for amino acid 200- 239, but not other Ro52 epitopes, induce congenital heart block in a rat model. Ann Rheumatic Dis 2012;71:448-54.

9. SalomonssonS,SonessonSE,OttossonL,etal. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005;201:11-7.

DOI: doi.org/10.1136/ard.62.10.1010

10.

10. The PR interval and Dexamethasone evaluation (PRIDE) Prospective Study. Circulation. 2008;117:485-93.

11.

11. Gupta M, Hamilton R, Berul C et al. Pediatric congenital atrioventricular block. Medscape, Dec 6, 2011.

DOI: doi.org/10.1016/s8756-5005(10)79327-6

12.

12. Jaeggi ET, Fouron JC, Silverman ED et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation. 2004;110:1542-8.

13.

13. Nield LE, Silverman ED, Smallhorn JF et al. Endocardial ← broelastosis associated with maternal anti-Ro and anti La antibodies in the absence of atrioventricular block. Circulation. 2002;40:796–802.

14.

14. Puria S, Pooni P, Mohan B et al. Pregnancy With SLE and Fetal Congenital Heart Block: A Case Report. Cardiol Res. 2013;4:126-8.

DOI: doi.org/10.1136/annrheumdis-2011-200414

15.

15. RosenthalE. Classification of congenital complete heart block: autoantibody-associated or isolated? Lupus. 2003;12:425-6.

Tác giả

Cao Mạnh Hưng: Bác sĩ nội trú, Đại học Y Hà Nội; Nguyễn Thị Duyên: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai; Phạm Bá Nha: Khoa Phụ sản, Bệnh viện Bạch Mai; Trương Thanh Hương: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;